NORMAL SITUATION

MegaPharma

Export PDF

Financial year 2022 · closed on 30/11/2022

Net result

-3,7 k €

-670.0% YoY

Equity

13,2 k €

-22.1% YoY

Company — Normal situation.

What does MegaPharma do?

MegaPharma is a company registered in Belgium.

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0836.216.610

Legal form

Private company with limited liability

Contributed capital

20 000,00 €

Latest accounts

30/11/2022

Signals

Solid equity

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 12 financial years

	2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011
Income statement
Gross margin	–		–		–		-1,7 k €	-131%	5,4 k €	-27.3%	7,4 k €	+27.3%	5,8 k €	-21.3%	7,4 k €	+27.4%	5,8 k €	-29.3%	8,2 k €	-9.4%	9 k €	+157%	3,5 k €
EBITDA	-3,7 k €	-868%	-387 €	+81.4%	-2,1 k €	+7.4%	-2,2 k €	-147%	4,7 k €	-24.8%	6,3 k €	+21.0%	5,2 k €	-22.7%	6,7 k €	+26.6%	5,3 k €	-30.9%	7,7 k €	-9.0%	8,5 k €	+167%	3,2 k €
Operating result	-3,7 k €	-868%	-387 €	+81.4%	-2,1 k €	+7.4%	-2,2 k €	-147%	4,7 k €	-24.8%	6,3 k €	+21.0%	5,2 k €	-22.7%	6,7 k €	+26.6%	5,3 k €	-30.9%	7,7 k €	-9.0%	8,5 k €	+167%	3,2 k €
Net result	-3,7 k €	-670%	-483,9 €	+80.1%	-2,4 k €	+5.2%	-2,6 k €	-1654%	165,3 €	-52.3%	346,6 €	+40.8%	246,1 €	-77.2%	1,1 k €	+167%	405,9 €	+1.6%	399,6 €	-53.8%	865,6 €	+177%	-1,1 k €
Balance sheet
Equity	13,2 k €	-22.1%	16,9 k €	-2.8%	17,4 k €	-12.3%	19,8 k €	-11.5%	22,4 k €	+0.7%	22,2 k €	+1.6%	21,9 k €	+1.1%	21,6 k €	+5.3%	20,5 k €	+2.0%	20,1 k €	+2.0%	19,7 k €	+4.6%	18,9 k €
Total assets	13,2 k €	-22.1%	16,9 k €	-8.5%	18,5 k €	-43.5%	32,7 k €	-4.7%	34,3 k €	-27.5%	47,3 k €	-17.0%	57 k €	-31.1%	82,7 k €	-13.3%	95,4 k €	+70.5%	56 k €	-24.0%	73,7 k €	+139%	30,8 k €
Cash	13,2 k €	-20.7%	16,6 k €	-7.5%	18 k €	-42.4%	31,2 k €	-8.2%	34 k €	-28.1%	47,3 k €	+3.9%	45,5 k €	-34.9%	69,8 k €	-25.4%	93,6 k €	+113%	43,9 k €	-29.6%	62,3 k €	+153%	24,6 k €
Debts	–		–		1,1 k €	-91.6%	12,8 k €	+8.1%	11,9 k €	-52.5%	25 k €	-28.7%	35,1 k €	-42.5%	61 k €	-18.5%	74,9 k €	+109%	35,8 k €	-33.6%	53,9 k €	+358%	11,8 k €

Governance

Board of directors

Seen on filing of 30/11/2022 · 1 active · 7 ended

Active mandates

GJ LIFESCIENCES MANAGEMENT

Director · since 14 juillet 2021 · 0770.962.631

Active

Ended mandates

GJ LIFESCIENCES MANAGEMENT

Director · since 14 juillet 2021 · until 25 juin 2027 · 0770.962.631

Represented by GILLES JOURQUIN

Ended

JGO

Manager · since 17 décembre 2017 · until 25 mai 2023 · 0643.915.001

Represented by Jérôme GOBBESSO

Ended

JGO

Director · since 17 décembre 2017 · until 25 mai 2023 · 0643.915.001

Represented by Jérôme GOBBESSO

Ended

DEEP DIVE

Manager · 0895.939.411

Represented by JEROME GOBBESSO

Ended

Annual accounts

Full financial information

	2022	2021	2020	2019	2018	2017
Type of account	Full model	Full model	Full model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2022	01/01/2021	01/01/2020	01/01/2019	01/01/2018	01/01/2017
Closing of the financial year	30/11/2022	31/12/2021	31/12/2020	31/12/2019	31/12/2018	31/12/2017
Length of the financial year	11 months	12 months	12 months	12 months	12 months	12 months
Filing date	01/03/2023	06/07/2022	28/07/2021	14/08/2020	25/07/2019	10/07/2018
General meeting	–	30/06/2022	30/06/2021	30/07/2020	28/06/2019	21/06/2018
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

12 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Full model	30/11/2022	—	01/03/2023	French	PDF
Full model	31/12/2021	30/06/2022	06/07/2022	French	PDF
Full model	31/12/2020	30/06/2021	28/07/2021	French	PDF
Abridged model	31/12/2019	30/07/2020	14/08/2020	French	PDF
Abridged model	31/12/2018	28/06/2019	25/07/2019	French	PDF
Abridged model	31/12/2017	21/06/2018	10/07/2018	French	PDF
Abridged model	31/12/2016	30/06/2017	25/07/2017	French	PDF
Abridged model	31/12/2015	16/08/2016	31/08/2016	French	PDF
Abridged model	31/12/2014	31/07/2015	19/08/2015	French	PDF
Abridged model	31/12/2013	04/06/2014	19/06/2014	French	PDF
Abridged model	31/12/2012	30/06/2013	18/07/2013	French	PDF
Abridged model	31/12/2011	30/06/2012	06/07/2012	French	PDF

Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 30/11/2022 · 1 active · 7 ended

Active mandates

GJ LIFESCIENCES MANAGEMENT

Director · since 14 juillet 2021 · 0770.962.631

Active

Ended mandates

GJ LIFESCIENCES MANAGEMENT

Director · since 14 juillet 2021 · until 25 juin 2027 · 0770.962.631

Represented by GILLES JOURQUIN

Ended

JGO

Manager · since 17 décembre 2017 · until 25 mai 2023 · 0643.915.001

Represented by Jérôme GOBBESSO

Ended

JGO

Director · since 17 décembre 2017 · until 25 mai 2023 · 0643.915.001

Represented by Jérôme GOBBESSO

Ended

DEEP DIVE

Manager · 0895.939.411

Represented by JEROME GOBBESSO

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Court decision27/12/2022
RUBRIQUE FIN (CESSATION, ANNULATION CESSATION, NULLITE, CONC, REORGANISATION JUDICIAIRE, ETC...)
PDF
Mandates28/09/2021
DEMISSIONS, NOMINATIONS
PDF
Mandates26/02/2021
DEMISSIONS, NOMINATIONS - MODIFICATION FORME JURIDIQUE
PDF
Mandates22/07/2020
DEMISSIONS, NOMINATIONS
PDF
Mandates09/01/2018
DEMISSIONS, NOMINATIONS
PDF
Mandates26/02/2016
DEMISSIONS, NOMINATIONS
PDF
Mandates18/02/2015
SIEGE SOCIAL - DEMISSIONS, NOMINATIONS
PDF
Mandates06/04/2012
DENOMINATION - SIEGE SOCIAL - OBJET
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2022
Annual accounts 2022-3,7 k €↓
2021
Annual accounts 2021-483,9 €↑
2020
Annual accounts 2020-2,4 k €↑
2019
Annual accounts 2019-2,6 k €↓
2018
Annual accounts 2018165,3 €↓
2017
Annual accounts 2017346,6 €↑
2016
Annual accounts 2016246,1 €↓
2015
Annual accounts 20151,1 k €↑
2014
Annual accounts 2014405,9 €↑
2013
Annual accounts 2013399,6 €↓
2012
Annual accounts 2012865,6 €↑
2011
Annual accounts 2011-1,1 k €

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

MegaPharma

Overview

What does MegaPharma do?

Trend over 12 financial years

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline